Table 3. Clinical Outcomes with Aspirin or Placebo.

Outcome	Aspirin (N = 2860)	Placebo (N = 2853)	Hazard Ratio (95% CI)*
Primary outcome
Death from cardiovascular causes, myocardial infarction, or stroke — no. (%)	116 (4.1)	134 (4.7)	0.86 (0.67–1.10)
Secondary Outcome
Death from cardiovascular causes, myocardial infarction, stroke, or cancer — no. (%)	153 (5.3)	177 (6.2)	0.86 (0.69–1.07)
Components of the primary and secondary outcomes
Death from cardiovascular causes — no. (%)†	85 (3.0)	100 (3.5)	0.85 (0.64–1.14)
Myocardial infarction — no. (%)	22 (0.8)	21 (0.7)	1.04 (0.57–1.89)
Stroke — no. (%)	23 (0.8)	39 (1.4)	0.58 (0.35–0.98)
Cancer — no. (%)	38 (1.3)	46 (1.6)	0.83 (0.54–1.27)
Other efficacy outcomes
Death from any cause — no. (%)	145 (5.1)	167 (5.9)	0.87 (0.70–1.09)
First and recurrent events of the primary outcome
No. of participants with ≥1 event	116	134	—
No. of participants with ≥2 events	8	10	—
Total no. of events	124	144	0.86 (0.67–1.11)‡
First and recurrent events of the secondary outcome
No. of participants with ≥1 event	153	177	—
No. of participants with ≥2 events	12	17	—
Total no. of events	165	194	0.85 (0.68–1.06)‡

^*The widths of the confidence intervals have not been adjusted for multiplicity, so the intervals should not be used to infer definitive treatment effects.

^†Death from cardiovascular causes included confirmed death from cardiovascular causes (in 68 participants in the aspirin group and in 69 in the placebo group) and death from an unknown cause, which was categorized according to the protocol definition as presumed death from cardiovascular causes (in 17 and 31 participants, respectively).

^‡The analysis was conducted with the use of a proportional-means model.